178 related articles for article (PubMed ID: 21428914)
1. mTOR Signalling in Health and Disease.
Proud CG
Biochem Soc Trans; 2011 Apr; 39(2):431-6. PubMed ID: 21428914
[TBL] [Abstract][Full Text] [Related]
2. mTOR-what does it do?
Hall MN
Transplant Proc; 2008 Dec; 40(10 Suppl):S5-8. PubMed ID: 19100909
[TBL] [Abstract][Full Text] [Related]
3. Evolutionarily conserved regulation of TOR signalling.
Takahara T; Maeda T
J Biochem; 2013 Jul; 154(1):1-10. PubMed ID: 23698095
[TBL] [Abstract][Full Text] [Related]
4. Role of PRAS40 in Akt and mTOR signaling in health and disease.
Wiza C; Nascimento EB; Ouwens DM
Am J Physiol Endocrinol Metab; 2012 Jun; 302(12):E1453-60. PubMed ID: 22354785
[TBL] [Abstract][Full Text] [Related]
5. mTOR in aging, metabolism, and cancer.
Cornu M; Albert V; Hall MN
Curr Opin Genet Dev; 2013 Feb; 23(1):53-62. PubMed ID: 23317514
[TBL] [Abstract][Full Text] [Related]
6. TORC1 of fission yeast is rapamycin-sensitive.
Takahara T; Maeda T
Genes Cells; 2012 Aug; 17(8):698-708. PubMed ID: 22762302
[TBL] [Abstract][Full Text] [Related]
7. mTORC1 regulates the efficiency and cellular capacity for protein synthesis.
Proud CG
Biochem Soc Trans; 2013 Aug; 41(4):923-6. PubMed ID: 23863157
[TBL] [Abstract][Full Text] [Related]
8. Steady-state kinetic and inhibition studies of the mammalian target of rapamycin (mTOR) kinase domain and mTOR complexes.
Tao Z; Barker J; Shi SD; Gehring M; Sun S
Biochemistry; 2010 Oct; 49(39):8488-98. PubMed ID: 20804212
[TBL] [Abstract][Full Text] [Related]
9. Mammalian target of rapamycin and the kidney. I. The signaling pathway.
Lieberthal W; Levine JS
Am J Physiol Renal Physiol; 2012 Jul; 303(1):F1-10. PubMed ID: 22419691
[TBL] [Abstract][Full Text] [Related]
10. mTORC1- and mTORC2-interacting proteins keep their multifunctional partners focused.
Bracho-Valdés I; Moreno-Alvarez P; Valencia-Martínez I; Robles-Molina E; Chávez-Vargas L; Vázquez-Prado J
IUBMB Life; 2011 Oct; 63(10):896-914. PubMed ID: 21905202
[TBL] [Abstract][Full Text] [Related]
11. Who does TORC2 talk to?
Xie J; Wang X; Proud CG
Biochem J; 2018 May; 475(10):1721-1738. PubMed ID: 29794170
[TBL] [Abstract][Full Text] [Related]
12. Role of TSC-mTOR pathway in diabetic nephropathy.
Inoki K
Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S59-62. PubMed ID: 18926585
[TBL] [Abstract][Full Text] [Related]
13. Growing roles for the mTOR pathway.
Sarbassov DD; Ali SM; Sabatini DM
Curr Opin Cell Biol; 2005 Dec; 17(6):596-603. PubMed ID: 16226444
[TBL] [Abstract][Full Text] [Related]
14. Target of rapamycin signaling in leukemia and lymphoma.
Vu C; Fruman DA
Clin Cancer Res; 2010 Nov; 16(22):5374-80. PubMed ID: 20826559
[TBL] [Abstract][Full Text] [Related]
15. mTOR in health and in sickness.
Liko D; Hall MN
J Mol Med (Berl); 2015 Oct; 93(10):1061-73. PubMed ID: 26391637
[TBL] [Abstract][Full Text] [Related]
16. [TOR-centric concept of regulation mitogenic, metabolic and energetic signal processing in cell].
Zubova SG; Shitikova ZhV; Pospelova TV
Tsitologiia; 2012; 54(8):589-602. PubMed ID: 23074850
[TBL] [Abstract][Full Text] [Related]
17. Effects of rapamycin and TOR on aging and memory: implications for Alzheimer's disease.
Santos RX; Correia SC; Cardoso S; Carvalho C; Santos MS; Moreira PI
J Neurochem; 2011 Jun; 117(6):927-36. PubMed ID: 21447003
[TBL] [Abstract][Full Text] [Related]
18. Complexity of the TOR signaling network.
Inoki K; Guan KL
Trends Cell Biol; 2006 Apr; 16(4):206-12. PubMed ID: 16516475
[TBL] [Abstract][Full Text] [Related]
19. Mammalian target of rapamycin signaling in the podocyte.
Inoki K; Huber TB
Curr Opin Nephrol Hypertens; 2012 May; 21(3):251-7. PubMed ID: 22388550
[TBL] [Abstract][Full Text] [Related]
20. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive.
Jacinto E; Loewith R; Schmidt A; Lin S; Rüegg MA; Hall A; Hall MN
Nat Cell Biol; 2004 Nov; 6(11):1122-8. PubMed ID: 15467718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
